RNAi therapy from Medicines Co., Alnylam cuts cholesterol by 54%, could compete with PCSK9 mAbs

The Medicines Co. announced data from a Phase III trial of inclisiran showing reductions in LDL-C that appear to be competitive with approved mAbs against PCSK9, but with a dosing advantage. Safety data from the study, which tested the RNAi therapeutic in patients with hypercholesterolemia

Read the full 455 word article

User Sign In